在患有多发性硬化症和下泌尿道功能障碍的患者中神经神经调节的有效性和安全性:系统性审查和元分析
Carlos Ferreira1,2, Paula Soeiro2, Sara Fonseca2
1Serviço de Urologia, Centro Hospitalar Universitário de São João, Porto, Portugal.
Neurourology and urodynamics
|October 22, 2025
概括
圣神经调节 (SNM) 在治疗多发性硬化症 (MS) 患者的神经性下尿路功能障碍方面显示出有前途,成功率高. 需要进一步的研究来确认其长期的疗效和安全性.
科学领域:
- 神经学 神经学
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 医疗技术 医疗技术 医学技术
背景情况:
- 与多发性硬化症 (MS) 相关的神经性下尿路功能障碍 (ANLUTD) 提出了重大治疗挑战.
- 对ANLUTD的保守疗法经常是无效的,需要先进的治疗选择.
研究的目的:
- 系统地审查神经神经调节 (SNM) 治疗MS成年患者ANLUTD的疗效和安全性.
- 评估SNM在这个特定患者群体中的当前证据基础.
主要方法:
- 通过PubMed和Scopus进行了全面的文献搜索,并通过手动搜索进行了补充.
- 包括的研究是原始研究文章,重点是SNM对ANLUTD的MS患者尿路症状的影响.
- 使用牛津证据医学中心的标准和ROBINS-I工具严格评估证据质量.
主要成果:
- 分析了包括192名接受SNM的MS患者在内的17项研究.
- 在试验阶段,SNM的总体成功率为80%,在永久植入阶段为74%.
- 综合的并发症发生率约为7%,大多数是轻微的和可控的.
结论:
- 圣神经调节显示出在MS相关的ANLUTD中改善尿路症状的潜力.
- 目前的证据质量很低,这强调了需要高质量的随机临床试验.
- 进一步的研究是必不可少的,以确定在这个人群中SNM的长期疗效和安全性.
相关概念视频
01:37Neural Regulation
34.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.8K
01:15Drug Dosing: Geriatric Patients
402
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
402
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
387
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
387